EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...
Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...
At the same time, VIS-101 is also an important driver, and I apologise for now focusing on it too much. It provides a second leg to the story here, with a Phase 2b initiation expected sometime in 2H26 ...
An AI-Powered Job Discovery and Recruitment Platform with privacy-first local LLMs, intelligent candidate-to-job matching, skill graph mapping, and delta resume storage. FINDING_AI is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results